KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) Research & Development (2017 - 2025)

Historic Research & Development for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to $90.0 million.

  • Guardant Health's Research & Development rose 303.64% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $359.5 million, marking a year-over-year increase of 447.7%. This contributed to the annual value of $347.8 million for FY2024, which is 529.45% down from last year.
  • Per Guardant Health's latest filing, its Research & Development stood at $90.0 million for Q3 2025, which was up 303.64% from $87.4 million recorded in Q2 2025.
  • Guardant Health's 5-year Research & Development high stood at $106.6 million for Q4 2022, and its period low was $55.5 million during Q1 2021.
  • For the 5-year period, Guardant Health's Research & Development averaged around $85.2 million, with its median value being $87.4 million (2025).
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 9580.08% in 2021, then crashed by 1568.99% in 2023.
  • Over the past 5 years, Guardant Health's Research & Development (Quarter) stood at $73.0 million in 2021, then skyrocketed by 45.96% to $106.6 million in 2022, then dropped by 15.69% to $89.9 million in 2023, then grew by 4.1% to $93.5 million in 2024, then decreased by 3.83% to $90.0 million in 2025.
  • Its Research & Development stands at $90.0 million for Q3 2025, versus $87.4 million for Q2 2025 and $88.5 million for Q1 2025.